Srikripa Devarakonda
Stock Analyst at Truist Financial
(4.92)
# 216
Out of 5,005 analysts
520
Total ratings
59.5%
Success rate
26.6%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding | Reiterated: Buy | $76 → $77 | $49.13 | +56.73% | 33 | Sep 24, 2026 | |
| AXSM Axsome Therapeutics | Initiated Coverage: Buy | $285 | $193.85 | +47.02% | 1 | Sep 23, 2026 | |
| EWTX Edgewise Therapeutics | Reiterated: Buy | n/a | $39.79 | - | 35 | Sep 23, 2026 | |
| NAMS NewAmsterdam Pharma Company | Reiterated: Buy | $57 | $23.58 | +141.73% | 6 | Sep 22, 2026 | |
| IVA Inventiva | Reiterated: Buy | n/a | $3.53 | - | 6 | Sep 15, 2026 | |
| ABCL AbCellera Biologics | Reiterated: Buy | $30 | $13.92 | +115.52% | 14 | Sep 2, 2026 | |
| CYTK Cytokinetics | Reiterated: Buy | $112 | $66.16 | +69.29% | 40 | Sep 1, 2026 | |
| PTGX Protagonist Therapeutics | Reiterated: Buy | n/a | $142.59 | - | 25 | Sep 1, 2026 | |
| CORT Corcept Therapeutics | Initiated Coverage: Buy | $164 | $115.63 | +41.83% | 1 | Aug 18, 2026 | |
| OABI OmniAb | Reiterated: Buy | n/a | $4.74 | - | 9 | Aug 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $43 → $59 | $39.74 | +48.47% | 7 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1,376 | $1,184.78 | +16.14% | 38 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $10 → $8.68 | $7.51 | +15.58% | 16 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $88 | $57.54 | +52.94% | 11 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 | $63.88 | +9.58% | 22 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $709 | $517.72 | +36.95% | 15 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.96 | - | 4 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $124.82 | - | 37 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.96 | - | 1 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 → $17 | $9.49 | +79.14% | 10 | Jul 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $136 | $112.00 | +21.43% | 23 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $12.69 | - | 1 | Jun 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $11.28 | - | 21 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.8314 | - | 6 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $418.13 | - | 15 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $139 → $214 | $117.67 | +81.86% | 2 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $23.67 | -2.83% | 15 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $812 | $752.25 | +7.94% | 14 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $84 | $87.85 | -4.38% | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.14 | n/a | 8 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $142 | $228.69 | n/a | 12 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.29 | n/a | 7 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $266.28 | n/a | 7 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $148.69 | n/a | 8 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $28.72 | n/a | 10 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 15 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.29 | n/a | 3 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $71.81 | n/a | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 | $7.77 | n/a | 13 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $38 | $0.0001 | n/a | 7 | Mar 20, 2023 |
Scholar Rock Holding
Sep 24, 2026
Reiterated: Buy
Price Target: $76 → $77
Current: $49.13
Upside: +56.73%
Axsome Therapeutics
Sep 23, 2026
Initiated Coverage: Buy
Price Target: $285
Current: $193.85
Upside: +47.02%
Edgewise Therapeutics
Sep 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $39.79
Upside: -
NewAmsterdam Pharma Company
Sep 22, 2026
Reiterated: Buy
Price Target: $57
Current: $23.58
Upside: +141.73%
Inventiva
Sep 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.53
Upside: -
AbCellera Biologics
Sep 2, 2026
Reiterated: Buy
Price Target: $30
Current: $13.92
Upside: +115.52%
Cytokinetics
Sep 1, 2026
Reiterated: Buy
Price Target: $112
Current: $66.16
Upside: +69.29%
Protagonist Therapeutics
Sep 1, 2026
Reiterated: Buy
Price Target: n/a
Current: $142.59
Upside: -
Corcept Therapeutics
Aug 18, 2026
Initiated Coverage: Buy
Price Target: $164
Current: $115.63
Upside: +41.83%
OmniAb
Aug 18, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.74
Upside: -
Aug 13, 2026
Reiterated: Buy
Price Target: $43 → $59
Current: $39.74
Upside: +48.47%
Aug 11, 2026
Reiterated: Buy
Price Target: $1,376
Current: $1,184.78
Upside: +16.14%
Aug 10, 2026
Rated: Hold
Price Target: $10 → $8.68
Current: $7.51
Upside: +15.58%
Aug 10, 2026
Reiterated: Buy
Price Target: $88
Current: $57.54
Upside: +52.94%
Jul 31, 2026
Reiterated: Buy
Price Target: $70
Current: $63.88
Upside: +9.58%
Jul 31, 2026
Reiterated: Buy
Price Target: $709
Current: $517.72
Upside: +36.95%
Jul 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.96
Upside: -
Jul 29, 2026
Reiterated: Hold
Price Target: n/a
Current: $124.82
Upside: -
Jul 27, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.96
Upside: -
Jul 2, 2026
Reiterated: Buy
Price Target: $11 → $17
Current: $9.49
Upside: +79.14%
Jun 29, 2026
Rated: Buy
Price Target: $136
Current: $112.00
Upside: +21.43%
Jun 8, 2026
Reiterated: Hold
Price Target: n/a
Current: $12.69
Upside: -
May 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $11.28
Upside: -
Mar 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.8314
Upside: -
Nov 5, 2025
Reiterated: Hold
Price Target: n/a
Current: $418.13
Upside: -
Nov 3, 2025
Reiterated: Buy
Price Target: $139 → $214
Current: $117.67
Upside: +81.86%
Oct 30, 2025
Reiterated: Buy
Price Target: $23
Current: $23.67
Upside: -2.83%
Oct 29, 2025
Reiterated: Buy
Price Target: $812
Current: $752.25
Upside: +7.94%
Oct 10, 2025
Reiterated: Buy
Price Target: $84
Current: $87.85
Upside: -4.38%
Aug 4, 2025
Rated: Hold
Price Target: n/a
Current: $1.14
Upside: n/a
Jul 21, 2025
Downgraded: Hold
Price Target: $142
Current: $228.69
Upside: n/a
Jul 9, 2025
Rated: Hold
Price Target: n/a
Current: $1.29
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $266.28
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $148.69
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $28.72
Upside: n/a
Jan 28, 2025
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Dec 23, 2024
Rated: Hold
Price Target: n/a
Current: $1.29
Upside: n/a
Nov 12, 2024
Reiterated: Buy
Price Target: n/a
Current: $71.81
Upside: n/a
Oct 18, 2024
Rated: Buy
Price Target: $15
Current: $7.77
Upside: n/a
Mar 20, 2023
Downgraded: Hold
Price Target: $40 → $38
Current: $0.0001
Upside: n/a